Literature DB >> 6223253

[Successful treatment of brain metastases in breast cancer with blood-brain barrier-impervious cytostatics and hormones].

S Mende, F Bleichner, P Stoeter, G Meuret.   

Abstract

11 patients (age 36-60 years) with breast cancer and CT-scan documented brain metastases (BM) were treated with hormonochemotherapy: 5-fluorouracil 500 mg/m2 i.v. day 1 + 8, adriamycin 50 mg/m2 i.v. day 1, cyclophosphamide 500 mg/m2 i.v. day 1-q4 weeks (FAC) and tamoxifen (TXF) 20 mg/day per os. Ovarectomy was carried out in 3 praemenopausal patients. In 3 cases single BM were surgically resected (2 subtotal, 1 total). One patient was shunted due to a hydrocephalus occlusus. Complete response (CR), i.e. normalization of CT-scan and disappearance of CNS related symptoms, was achieved in 9 out of 11 patients. One patient with partial remission (PR) and another with progressive disease died 6 and 5 months after diagnosis of BM. The median duration of remissions of all patients was 12 (5-43) months. The median survival time from diagnosis of BM was 15 (5-44) months and from mastectomy 46 (26-142) months. The cumulative probability of surviving was 63% one year after diagnosis of BM. One relapsing patient achieved a second CR, another a PR by whole brain irradiation. 4 patients survived more than 18 months from the diagnosis of BM. It appears that chemo-hormonotherapy provides a rational approach to palliation in breast cancer patients with BM in prolonging the survival.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6223253     DOI: 10.1159/000215201

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  2 in total

1.  Brain metastases from breast cancer may respond to endocrine therapy.

Authors:  R Colomer; D Cosos; J M Del Campo; M Boada; D Rubio; L Salvador
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

2.  Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.

Authors:  Robert J Morgan; Timothy Synold; Adam Mamelak; Dean Lim; Zaid Al-Kadhimi; Przemyslaw Twardowski; Lucille Leong; Warren Chow; Kim Margolin; Stephen Shibata; George Somlo; Yun Yen; Paul Frankel; James H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  2010-01-28       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.